Considerations for the Use of Mutation as a Regulatory Endpoint in Risk Assessment.

Klapacz, Joanna; Gollapudi, B Bhaskar

Klapacz, Joanna; Gollapudi, B Bhaskar.

Affiliation

Klapacz J; Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan.
Gollapudi BB; Center for Health Sciences, Exponent, Inc., Alexandria, Virginia.

Environ Mol Mutagen ; 61(1): 84-93, 2020 01.

Article in En | MEDLINE | ID: mdl-31301246

Subject(s)

Mutagenicity Tests/methods; Mutagens/toxicity; Mutation/drug effects; Animals; DNA Damage/drug effects; DNA Repair/drug effects; Humans; Risk Assessment/methods; Signal Transduction/drug effects

Key words

dose-response; exposure; mutagenicity; point-of-departure; thresholds

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Mutagenicity Tests / Mutagens / Mutation Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Year: 2020 Type: Article

Fulltext

XML

PubMed Links

Search on Google